Girard Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Girard Partners’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-400	Closed	-$55K	–	907
2018 Q3	$55K	Buy	+400	New	+$50.2K	0.01%	430

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Girard Partners's ALXN Position: Q4 2018 in Review

Girard Partners sold out of Alexion Pharmaceuticals (ALXN) in Q4 2018, closing a stake of 400 shares — an estimated $55K sold.

Girard Partners first reported a position in ALXN in Q3 2018 and held it in 1 quarter. The position peaked at $55K in Q3 2018. 608 funds tracked by Wall St. Rank hold ALXN as of Q4 2018.

Girard Partners reported no remaining Alexion Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Girard Partners sold 400 Alexion Pharmaceuticals shares in Q4 2018, an estimated $55K.
Girard Partners first reported a position in Alexion Pharmaceuticals in Q3 2018 and held it in 1 quarter.
Girard Partners's Alexion Pharmaceuticals position peaked at $55K in Q3 2018.
608 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2018.

Based on Girard Partners's 13F filing for Q4 2018, filed 11 Feb 2019.